A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Clinical trial NCT01209130 · COMPLETED

Trial details

NCT number: NCT01209130
Sponsor: Genentech, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia

Start date: 2010-10-01
Primary completion: 2015-03-01
Enrollment: 91

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.